Meralgia paresthetica is a condition characterized by tingling, numbness, and burning pain in the outer thigh due to compression of the lateral femoral cutaneous nerve. Companies involved in the field of meralgia paresthetica may focus on various aspects, including diagnostics, treatments, and supportive measures.
Boston Scientific Received FDA approval for its Veritasâ„¢ Spinal Cord Stimulation (SCS) System, which can be used to treat chronic pain, including MP. This system offers advanced features like MRI compatibility and directional leads for targeted pain relief.
Abbott Laboratories Expanded its portfolio with the Proclaimâ„¢ SCS System, featuring small, MRI-compatible leads designed for long-term pain management. Proclaimâ„¢ is also being investigated for its potential in treating MP.
Medtronic Continues to dominate the SCS market with its established systems like Stimwave®. Medtronic is also actively involved in research on improving SCS technology and expanding its applications to treat various pain conditions, including MP.
Saluda Medical emerging company developed the NervBlocâ„¢ radiofrequency ablation system, a minimally invasive approach for treating nerve pain like MP. NervBlocâ„¢ offers a shorter procedure time and potentially faster pain relief compared to traditional surgery.
Veritas Spine Another promising player, Veritas Spine focuses on developing innovative spinal cord stimulation technologies. Their SculpSureâ„¢ SCS System features micro-sculpted leads designed for precise pain relief and is being evaluated for its effectiveness in treating MP.
List of Meralgia Paresthetica Key Companies in the Market
Meralgia Paresthetica Market Highlights:
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)